Related Experiment Videos
Nafazatrom: clonogenic in-vitro assessment of activity against human malignancies
Abstract:
Nafazatrom was tested against a variety of human malignancies with the human tumor stem cell assay at one or more of the following concentrations: 1, 10, 25, and 100 micrograms/ml X 1 h or 0.05, 0.5, or 5 micrograms/ml by continuous exposure. Major (greater than or equal to 70%) inhibition was noted in 7/52 adenocarcinomas, in 0/9 squamous carcinomas, and 1/17 other malignancies. Intermediate levels of inhibition (50 to 69%) were noted in 7/52, 4/9, and 6/17 of these respective subtypes. No clear trend toward superiority of any dose-schedule was noted. Since nafazatrom has proven non-toxic in our nearly completed Phase I study, and since this study suggests activity against several human cancers, Phase II level testing is warranted.
Insights
Nafazatrom demonstrated significant anti-cancer activity against human adenocarcinomas and other malignancies in vitro. Further Phase II trials are recommended to explore its therapeutic potential in cancer treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Nafazatrom is an investigational compound with potential anti-cancer properties.
- Previous studies indicated non-toxicity in Phase I trials.
Purpose of the Study:
- To evaluate the efficacy of Nafazatrom against various human malignancies using the human tumor stem cell assay.
- To determine optimal dosing and scheduling for Nafazatrom treatment.
Main Methods:
- Human tumor stem cell assay was employed to test Nafazatrom.
- Testing involved concentrations of 1-100 µg/ml (1-hour exposure) and 0.05-5 µg/ml (continuous exposure).
- Tumor subtypes included adenocarcinomas, squamous carcinomas, and other malignancies.
Main Results:
- Major inhibition (≥70%) observed in 7/52 adenocarcinomas and 1/17 other malignancies.
- Intermediate inhibition (50-69%) observed in 7/52 adenocarcinomas, 4/9 squamous carcinomas, and 6/17 other malignancies.
- No significant difference in efficacy was noted across different dose schedules.
Conclusions:
- Nafazatrom exhibits activity against several human cancer types, particularly adenocarcinomas.
- The compound's non-toxic profile and demonstrated in vitro activity support further clinical investigation.
- Phase II clinical trials are warranted to assess Nafazatrom's therapeutic potential in cancer patients.